NASDAQ · SCNXHealthcarePharmaceuticals

Scienture Holdings financials

$0.2666−1.15%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
Revenue$431.6K$136.6K
Gross profit$331.5K$6.0K
Gross margin76.8%4.4%
Operating income-$42.6M-$14.7M
Net income-$41.5M$9.1M
Net margin−9618.0%6634.7%
Diluted EPS$-2.70$2.48
EBITDA-$13.7M-$12.9M
Operating cash flow-$13.4M-$14.3M
Free cash flow-$13.4M-$14.3M
Diluted shares15.3M3.7M

Balance sheet

Period endDec 31Dec 31
Cash & equivalents$6.7M$308.1K
Short-term investments$0.00$0.00
Total debt$0.00$3.3M
Total assets$84.2M$104.9M
Total liabilities$14.1M$25.8M
Shareholders' equity$70.1M$79.1M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology